Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
Abstract Aims/Introduction Increased incidence of hospitalization for heart failure (HHF) among patients with diabetes is increasingly being reported. We investigated the incidence of adverse cardiovascular events including HHF among patients with type 2 diabetes mellitus, and the potential clinical...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | Journal of Diabetes Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1111/jdi.13485 |
id |
doaj-7cb86a63caca4b45b63495cfa5283ebe |
---|---|
record_format |
Article |
spelling |
doaj-7cb86a63caca4b45b63495cfa5283ebe2021-08-10T18:00:48ZengWileyJournal of Diabetes Investigation2040-11162040-11242021-08-011281452146110.1111/jdi.13485Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho databaseShun Kohsaka0Hiraku Kumamaru1Shiori Nishimura2Satoshi Shoji3Eiji Nakatani4Nao Ichihara5Hiroyuki Yamamoto6Yoshiki Miyachi7Hiroaki Miyata8Department of Cardiology Keio University School of Medicine Tokyo JapanResearch Support Center Shizuoka General Hospital Shizuoka JapanResearch Support Center Shizuoka General Hospital Shizuoka JapanDepartment of Cardiology Keio University School of Medicine Tokyo JapanResearch Support Center Shizuoka General Hospital Shizuoka JapanResearch Support Center Shizuoka General Hospital Shizuoka JapanResearch Support Center Shizuoka General Hospital Shizuoka JapanResearch Support Center Shizuoka General Hospital Shizuoka JapanResearch Support Center Shizuoka General Hospital Shizuoka JapanAbstract Aims/Introduction Increased incidence of hospitalization for heart failure (HHF) among patients with diabetes is increasingly being reported. We investigated the incidence of adverse cardiovascular events including HHF among patients with type 2 diabetes mellitus, and the potential clinical improvement with sodium–glucose cotransporter 2 inhibitors (SGLT2i) using a contemporary administrative claims database from a large governmental district of Japan. Materials and Methods We included initiators of any oral glucose‐lowering drugs between 2013 and 2018. We estimated the 5‐year cumulative incidence of hospitalization for HF, myocardial infarction and stroke, treating death as a competing risk. We evaluated the possible impact of introducing SGLT2i to the potential recipients of the drug, using the inclusion criteria from Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA‐REG OUTCOME) and Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58 (DECLARE‐TIMI 58) trials, assuming the same risk reduction as theirs. Results Among 23,340 drug initiators (54.0% men, and 6.4% aged >85 years), the 5‐year cumulative incidence was 5.4% (95% confidence interval 4.9–5.9%) for HHF, 1.9% (95% confidence interval 1.7–2.2%) for myocardial infarction admission and 6.1% (95% confidence interval 5.7–6.6%) for stroke admission. Among 6,192 patients with laboratory test data, 651 (10.5%) and 2,680 (43.3%) patients met the EMPA‐REG‐like and DECLARE‐like criteria, respectively. The 5‐year cumulative incidence among the 2,849 patients meeting either of the criteria was estimated to decrease from 97.1 to 75.6 events through 75% adoption of SGLT2i. Conclusions The incidence of HHF was similar to that of stroke. A significant portion of our cohort met the inclusion criteria for major randomized clinical trials for SGLT2i, and estimated reduction in the HHF events was substantial.https://doi.org/10.1111/jdi.13485Cardiovascular diseaseHeart failureSodium–glucose cotransporter 2 inhibitors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shun Kohsaka Hiraku Kumamaru Shiori Nishimura Satoshi Shoji Eiji Nakatani Nao Ichihara Hiroyuki Yamamoto Yoshiki Miyachi Hiroaki Miyata |
spellingShingle |
Shun Kohsaka Hiraku Kumamaru Shiori Nishimura Satoshi Shoji Eiji Nakatani Nao Ichihara Hiroyuki Yamamoto Yoshiki Miyachi Hiroaki Miyata Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database Journal of Diabetes Investigation Cardiovascular disease Heart failure Sodium–glucose cotransporter 2 inhibitors |
author_facet |
Shun Kohsaka Hiraku Kumamaru Shiori Nishimura Satoshi Shoji Eiji Nakatani Nao Ichihara Hiroyuki Yamamoto Yoshiki Miyachi Hiroaki Miyata |
author_sort |
Shun Kohsaka |
title |
Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database |
title_short |
Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database |
title_full |
Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database |
title_fullStr |
Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database |
title_full_unstemmed |
Incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database |
title_sort |
incidence of adverse cardiovascular events in type 2 diabetes mellitus patients after initiation of glucose‐lowering agents: a population‐based community study from the shizuoka kokuho database |
publisher |
Wiley |
series |
Journal of Diabetes Investigation |
issn |
2040-1116 2040-1124 |
publishDate |
2021-08-01 |
description |
Abstract Aims/Introduction Increased incidence of hospitalization for heart failure (HHF) among patients with diabetes is increasingly being reported. We investigated the incidence of adverse cardiovascular events including HHF among patients with type 2 diabetes mellitus, and the potential clinical improvement with sodium–glucose cotransporter 2 inhibitors (SGLT2i) using a contemporary administrative claims database from a large governmental district of Japan. Materials and Methods We included initiators of any oral glucose‐lowering drugs between 2013 and 2018. We estimated the 5‐year cumulative incidence of hospitalization for HF, myocardial infarction and stroke, treating death as a competing risk. We evaluated the possible impact of introducing SGLT2i to the potential recipients of the drug, using the inclusion criteria from Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA‐REG OUTCOME) and Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58 (DECLARE‐TIMI 58) trials, assuming the same risk reduction as theirs. Results Among 23,340 drug initiators (54.0% men, and 6.4% aged >85 years), the 5‐year cumulative incidence was 5.4% (95% confidence interval 4.9–5.9%) for HHF, 1.9% (95% confidence interval 1.7–2.2%) for myocardial infarction admission and 6.1% (95% confidence interval 5.7–6.6%) for stroke admission. Among 6,192 patients with laboratory test data, 651 (10.5%) and 2,680 (43.3%) patients met the EMPA‐REG‐like and DECLARE‐like criteria, respectively. The 5‐year cumulative incidence among the 2,849 patients meeting either of the criteria was estimated to decrease from 97.1 to 75.6 events through 75% adoption of SGLT2i. Conclusions The incidence of HHF was similar to that of stroke. A significant portion of our cohort met the inclusion criteria for major randomized clinical trials for SGLT2i, and estimated reduction in the HHF events was substantial. |
topic |
Cardiovascular disease Heart failure Sodium–glucose cotransporter 2 inhibitors |
url |
https://doi.org/10.1111/jdi.13485 |
work_keys_str_mv |
AT shunkohsaka incidenceofadversecardiovasculareventsintype2diabetesmellituspatientsafterinitiationofglucoseloweringagentsapopulationbasedcommunitystudyfromtheshizuokakokuhodatabase AT hirakukumamaru incidenceofadversecardiovasculareventsintype2diabetesmellituspatientsafterinitiationofglucoseloweringagentsapopulationbasedcommunitystudyfromtheshizuokakokuhodatabase AT shiorinishimura incidenceofadversecardiovasculareventsintype2diabetesmellituspatientsafterinitiationofglucoseloweringagentsapopulationbasedcommunitystudyfromtheshizuokakokuhodatabase AT satoshishoji incidenceofadversecardiovasculareventsintype2diabetesmellituspatientsafterinitiationofglucoseloweringagentsapopulationbasedcommunitystudyfromtheshizuokakokuhodatabase AT eijinakatani incidenceofadversecardiovasculareventsintype2diabetesmellituspatientsafterinitiationofglucoseloweringagentsapopulationbasedcommunitystudyfromtheshizuokakokuhodatabase AT naoichihara incidenceofadversecardiovasculareventsintype2diabetesmellituspatientsafterinitiationofglucoseloweringagentsapopulationbasedcommunitystudyfromtheshizuokakokuhodatabase AT hiroyukiyamamoto incidenceofadversecardiovasculareventsintype2diabetesmellituspatientsafterinitiationofglucoseloweringagentsapopulationbasedcommunitystudyfromtheshizuokakokuhodatabase AT yoshikimiyachi incidenceofadversecardiovasculareventsintype2diabetesmellituspatientsafterinitiationofglucoseloweringagentsapopulationbasedcommunitystudyfromtheshizuokakokuhodatabase AT hiroakimiyata incidenceofadversecardiovasculareventsintype2diabetesmellituspatientsafterinitiationofglucoseloweringagentsapopulationbasedcommunitystudyfromtheshizuokakokuhodatabase |
_version_ |
1721211954982289408 |